DIFFUSE MACULAR OEDEMA
Intravitreal triamcinolone acetonide or bevacizumab produce better short-term results than grid laser in the treatment of diffuse macular oedema but all three treatments produce similar results at one year, a comparative study suggests. The study, which involved 126 eyes, showed that eyes receiving intravitreal bevacizumab or triamcinolone had higher rates of anatomical and functional success at six months than did eyes that underwent grid laser treatment (p < 0.05 for both). However, by one year there was no significant difference between the groups in terms of visual stabilisation
(Sobaci et al, Ophthalmologica 2012; 227: 95-99).Â
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.